Abvc Biopharma (ABVC) Total Non-Current Liabilities (2019 - 2026)
Abvc Biopharma's (ABVC) quarterly Total Non-Current Liabilities came in at $122508.0 in Q4 2025, up 38303.76% YoY from N/an in Q4 2024, and down 98.17% on a QoQ basis from $6.7 million in Q3 2025.
Abvc Biopharma (ABVC) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 7 years of Total Non-Current Liabilities data on file, last reported at $122508.0 in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 38303.76% year-over-year to $122508.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $122508.0 (up 38303.76% YoY) and the FY2025 annual result came in at $122508.0, up 38303.76% from the prior year.
- Total Non-Current Liabilities eased to $122508.0 in Q4 2025, from $6.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $6.9 million in Q1 2025 to a low of $319.0 in Q4 2024.
- A 5-year average of $1.7 million and a median of $109581.5 in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities tumbled 99.91% — and 2025, when it jumped 577598.83%.
- Tracing ABVC's Total Non-Current Liabilities over 5 years: stood at $32522.0 in 2021, then sank by 92.49% to $2441.0 in 2022, then surged by 14123.39% to $347193.0 in 2023, then plunged by 99.91% to $319.0 in 2024, then jumped by 38303.76% to $122508.0 in 2025.
- The last three Total Non-Current Liabilities figures came in at $122508.0 (Q4 2025), $6.7 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 9.32 Bn |
| 10 | Abvc Biopharma | 24.43 Mn | 24.43 Mn | - | 7.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.10 Mn |
| Dec 31, 2025 | 122,508.00 |
| Sep 30, 2025 | 6.68 Mn |
| Jun 30, 2025 | 6.71 Mn |
| Mar 31, 2025 | 6.90 Mn |
| Dec 31, 2024 | 319.00 |
| Sep 30, 2024 | 6.42 Mn |
| Jun 30, 2024 | 105,548.00 |
| Mar 31, 2024 | 1,194.00 |
| Dec 31, 2023 | 347,193.00 |
| Sep 30, 2023 | 366,634.00 |
| Jun 30, 2023 | 1,268.00 |
| Mar 31, 2023 | 357,150.00 |
| Dec 31, 2022 | 2,441.00 |
| Sep 30, 2022 | 100,261.00 |
| Jun 30, 2022 | 113,615.00 |
| Mar 31, 2022 | 4.70 Mn |
| Dec 31, 2021 | 32,522.00 |
| Sep 30, 2021 | 40,008.00 |
| Jun 30, 2021 | 58,745.00 |